{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:51:41Z","timestamp":1793386301624,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003983","name":"National Headache Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014832","name":"American Headache Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014832","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005339","name":"American Academy of Neurology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"\n Background<\/jats:title>\n People with migraine report reduced health-related quality of life during ictal and interictal phases. However, most patient-reported outcome measures (PROMs) focus on impact during migraine episodes (ictal) or globally (both ictal and interictal), potentially neglecting interictal burden. This exploratory analysis evaluated correlations between the 4-item Migraine Interictal Burden Scale (MIBS-4) total score and other PROMs in people with migraine.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A\n post hoc<\/jats:italic>\n analysis was conducted using participant data from a galcanezumab phase 3, placebo-controlled, 3-month study, followed by a 3-month open-label extension in participants with prior treatment failures. Correlations were assessed between baseline MIBS-4 and disease characteristics, baseline MIBS-4 and demographics, and MIBS-4 and other PROMs\/monthly migraine headache days at baseline and at Month (M) 6, using Spearman\u2019s rank correlation coefficient (r\n s<\/jats:sub>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 462 participants were included (mean age: 45.8\u202fyears); 85.9% were female, 58.2% had episodic migraine and 41.8% had chronic migraine. At baseline, highest correlations with MIBS-4 were observed for Migraine Specific Quality of Life Questionnaire (MSQ)-total score, MSQ-Emotional Function (MSQ-EF), and the Patient Health Questionnaire (PHQ-9) score, which measures depressive symptoms (all\n p<\/jats:italic>\n \u202f&lt;\u202f0.001). Correlation analysis between MIBS-4 and MSQ-total score revealed moderate correlation at baseline (\n r<\/jats:italic>\n s<\/jats:sub>\n :\u20130.53) that transitioned to moderate-high at M6 (\n r<\/jats:italic>\n s<\/jats:sub>\n :\u20130.70). MIBS-4 was moderately correlated with PHQ-9 score at baseline (\n r<\/jats:italic>\n s<\/jats:sub>\n :0.55) and M6 (\n r<\/jats:italic>\n s<\/jats:sub>\n :0.55). The Migraine Disability Assessment score transitioned from moderate-low correlation at baseline (\n r<\/jats:italic>\n s<\/jats:sub>\n :0.41) to moderate at M6 (\n r<\/jats:italic>\n s<\/jats:sub>\n : 0.53) and Generalized Anxiety Disorder score had moderate-low correlation at both time points (\n r<\/jats:italic>\n s<\/jats:sub>\n :0.42\u20130.47). MIBS-4 had moderate-negligible correlation with monthly migraine headache days at baseline (\n r<\/jats:italic>\n s<\/jats:sub>\n :0.21) and low correlation at Month 6 (\n r<\/jats:italic>\n s<\/jats:sub>\n :0.32).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Interictal burden, as assessed by MIBS-4, was moderately correlated with PROMs like MSQ, PHQ-9, and MIDAS, but moderate-negligible to low correlation was observed with monthly migraine headache days. These results indicate that interictal burden is a unique construct that is correlated with, but not fully captured by, other measures and should be considered when managing people with migraine.<\/jats:p>\n <\/jats:sec>\n \n Clinical trial registration<\/jats:title>\n \n ClinicalTrials.gov<\/jats:ext-link>\n identifier NCT03559257.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fneur.2026.1808619","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:51:36Z","timestamp":1780671096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the relationship between the 4-item migraine interictal burden scale and other patient-reported outcome measures: a post hoc analysis from a phase 3 migraine prevention study"],"prefix":"10.3389","volume":"17","author":[{"given":"Christian","family":"Lampl","sequence":"first","affiliation":[{"name":"Hospital Barmherzige Br\u00fcder Linz","place":["Linz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine","place":["Bronx, NY, United States"]},{"name":"Montefiore Medical Center","place":["Bronx, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lipsius","sequence":"additional","affiliation":[{"name":"Syneos Health","place":["Morrisville, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet H.","family":"Ford","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Dell\u2019Agnello","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Viktrup","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine","place":["Bronx, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","article-title":"Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life","volume":"84","author":"Buse","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1032103","DOI":"10.3389\/fneur.2022.1032103","article-title":"The not so hidden impact of interictal burden in migraine. A narrative review","volume":"13","author":"Vincent","year":"2022","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S1474-4422(25)00402-8","article-title":"Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the global burden of disease study 2023","volume":"24","year":"2025","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11916-012-0263-1","article-title":"Why HURT? A review of clinical instruments for headache management","volume":"16","author":"Buse","year":"2012","journal-title":"Curr Pain Headache Rep"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-3-031-25938-8_4","volume-title":"Clinical Scales for Headache Disorders","author":"Buse","year":"2023"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1177\/0333102417731348","article-title":"Assessing the impact of headaches and the outcomes of treatment: a systematic review of patient-reported outcome measures (PROMs)","volume":"38","author":"Haywood","year":"2018","journal-title":"Cephalalgia"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1526-4610.2007.01004.x","article-title":"The migraine cycle: patient burden of migraine during and between migraine attacks","volume":"48","author":"Brandes","year":"2008","journal-title":"Headache"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1046\/j.1468-2982.1995.1501031.x","article-title":"Migraine patients experience poorer subjective well-being\/quality of life even between attacks","volume":"15","author":"Dahl\u00f6f","year":"1995","journal-title":"Cephalalgia"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40122-024-00589-3","article-title":"Acute treatment patterns, migraine burden, and healthcare resource use in people with migraine: results from the OVERCOME (EU) observational study","volume":"13","author":"Evers","year":"2024","journal-title":"Pain Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10194-016-0599-8","article-title":"Interictal burden attributable to episodic headache: findings from the Eurolight project","volume":"17","author":"Lampl","year":"2016","journal-title":"J Headache Pain"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1526-4610.2007.00843.x","article-title":"The migraine Interictal burden scale (MIBS): results of a population-based validation study [abstract F64]","volume":"47","author":"Buse","year":"2007","journal-title":"Headache"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s10194-022-01467-z","article-title":"Measuring interictal burden among people affected by migraine: a descriptive survey study","volume":"23","author":"Hubig","year":"2022","journal-title":"J Headache Pain"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e208074","DOI":"10.1212\/WNL.0000000000208074","article-title":"Migraine-related stigma and its relationship to disability, interictal burden, and quality of life: results of the OVERCOME (US) study","volume":"102","author":"Shapiro","year":"2024","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","article-title":"Galcanezumab in patients with multiple previous migraine preventive medication category failures: results from the open-label period of the CONQUER trial","volume":"38","author":"Reuter","year":"2021","journal-title":"Adv Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/head.14460","article-title":"Changes in migraine interictal burden following treatment with galcanezumab: results from a phase III randomized, placebo-controlled study","volume":"63","author":"Lipton","year":"2023","journal-title":"Headache"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1526-4610.2011.01997.x","article-title":"Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine","volume":"52","author":"Bagley","year":"2012","journal-title":"Headache"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.1999.019002107.x","article-title":"Reliability of the migraine disability assessment score in a population-based sample of headache sufferers","volume":"19","author":"Stewart","year":"1999","journal-title":"Cephalalgia"},{"key":"ref19","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"PharmacoEconomics"},{"key":"ref23","first-page":"69","article-title":"A guide to appropriate use of correlation coefficient in medical research","volume":"24","author":"Mukaka","year":"2012","journal-title":"Malawi Med J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","article-title":"Burden of migraine in Japan: results of the Observational survey of the epidemiology, treatment, and care of Migraine (OVERCOME [Japan]) study","volume":"11","author":"Matsumori","year":"2022","journal-title":"Neurol Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.13829","article-title":"United States patients' perspective of living with migraine: country-specific results from the global \u201cmy migraine voice\u201d survey","volume":"60","author":"Gibbs","year":"2020","journal-title":"Headache"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","article-title":"My migraine voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed","volume":"19","author":"Martelletti","year":"2018","journal-title":"J Headache Pain"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s10194-024-01927-8","article-title":"Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention","volume":"25","author":"Lampl","year":"2024","journal-title":"J Headache Pain"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1808619\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:51:38Z","timestamp":1780671098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1808619\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":27,"alternative-id":["10.3389\/fneur.2026.1808619"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1808619","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1808619"}}